Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach
- Autores
- Altirriba, Jordi; Barbera, Albert; del Zotto, Hector Herminio; Nadal, Belen; Piquer, Sandra; Sánchez Pla, Alex; Gagliardino, Juan Jose; Gomis, Ramon
- Año de publicación
- 2009
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Background: Sodium tungstate is known to be an effective anti-diabetic agent, able to increase beta cell mass in animal models of diabetes, although the molecular mechanisms of this treatment and the genes that control pancreas plasticity are yet to be identified. Using a transcriptomics approach, the aim of the study is to unravel the molecular mechanisms which participate in the recovery of exocrine and endocrine function of streptozotocin (STZ) diabetic rats treated with tungstate, determining the hyperglycemia contribution and the direct effect of tungstate. Results: Streptozotocin (STZ)-diabetic rats were treated orally with tungstate for five weeks. Treated (STZ)-diabetic rats showed a partial recovery of exocrine and endocrine function, with lower glycemia, increased insulinemia and amylasemia, and increased beta cell mass achieved by reducing beta cell apoptosis and raising beta cell proliferation. The microarray analysis of the pancreases led to the identification of three groups of differentially expressed genes: genes altered due to diabetes, genes restored by the treatment, and genes specifically induced by tungstate in the diabetic animals. The results were corroborated by quantitative PCR. A detailed description of the pathways involved in the pancreatic effects of tungstate is provided in this paper. Hyperglycemia contribution was studied in STZ-diabetic rats treated with phloridzin, and the direct effect of tungstate was determined in INS-1E cells treated with tungstate or serum from untreated or treated STZ-rats, observing that tungstate action in the pancreas takes places via hyperglycemia-independent pathways and via a combination of tungstate direct and indirect (through the serum profile modification) effects. Finally, the MAPK pathway was evaluated, observing that it has a key role in the tungstate-induced increase of beta cell proliferation as tungstate activates the mitogen-activated protein kinase (MAPK) pathway directly by increasing p42/p44 phosphorylation and indirectly by decreasing the expression of raf kinase inhibitor protein (Rkip), a negative modulator of the pathway. Conclusion: In conclusion, tungstate improves pancreatic function through a combination of hyperglycemia-independent pathways and through its own direct and indirect effects, whereas the MAPK pathway has a key role in the tungstate-induced increase of beta cell proliferation.
Fil: Altirriba, Jordi. Hospital Clinic de Barcelona; España. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España
Fil: Barbera, Albert. Hospital Clinic de Barcelona; España
Fil: del Zotto, Hector Herminio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina
Fil: Nadal, Belen. Hospital Clinic de Barcelona; España. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España
Fil: Piquer, Sandra. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España. Hospital Clinic de Barcelona; España
Fil: Sánchez Pla, Alex. Universidad Autónoma de Barcelona. Hospital Vall D' Hebron; España. Universidad de Barcelona; España
Fil: Gagliardino, Juan Jose. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
Fil: Gomis, Ramon. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España. Hospital Clinic de Barcelona; España - Materia
-
TUNGSTATO
CELULAS B
DIABETES
MASA DE CELULS B - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/96573
Ver los metadatos del registro completo
id |
CONICETDig_fee208ee93df2976090ddaebc60fd629 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/96573 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approachAltirriba, JordiBarbera, Albertdel Zotto, Hector HerminioNadal, BelenPiquer, SandraSánchez Pla, AlexGagliardino, Juan JoseGomis, RamonTUNGSTATOCELULAS BDIABETESMASA DE CELULS Bhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Background: Sodium tungstate is known to be an effective anti-diabetic agent, able to increase beta cell mass in animal models of diabetes, although the molecular mechanisms of this treatment and the genes that control pancreas plasticity are yet to be identified. Using a transcriptomics approach, the aim of the study is to unravel the molecular mechanisms which participate in the recovery of exocrine and endocrine function of streptozotocin (STZ) diabetic rats treated with tungstate, determining the hyperglycemia contribution and the direct effect of tungstate. Results: Streptozotocin (STZ)-diabetic rats were treated orally with tungstate for five weeks. Treated (STZ)-diabetic rats showed a partial recovery of exocrine and endocrine function, with lower glycemia, increased insulinemia and amylasemia, and increased beta cell mass achieved by reducing beta cell apoptosis and raising beta cell proliferation. The microarray analysis of the pancreases led to the identification of three groups of differentially expressed genes: genes altered due to diabetes, genes restored by the treatment, and genes specifically induced by tungstate in the diabetic animals. The results were corroborated by quantitative PCR. A detailed description of the pathways involved in the pancreatic effects of tungstate is provided in this paper. Hyperglycemia contribution was studied in STZ-diabetic rats treated with phloridzin, and the direct effect of tungstate was determined in INS-1E cells treated with tungstate or serum from untreated or treated STZ-rats, observing that tungstate action in the pancreas takes places via hyperglycemia-independent pathways and via a combination of tungstate direct and indirect (through the serum profile modification) effects. Finally, the MAPK pathway was evaluated, observing that it has a key role in the tungstate-induced increase of beta cell proliferation as tungstate activates the mitogen-activated protein kinase (MAPK) pathway directly by increasing p42/p44 phosphorylation and indirectly by decreasing the expression of raf kinase inhibitor protein (Rkip), a negative modulator of the pathway. Conclusion: In conclusion, tungstate improves pancreatic function through a combination of hyperglycemia-independent pathways and through its own direct and indirect effects, whereas the MAPK pathway has a key role in the tungstate-induced increase of beta cell proliferation.Fil: Altirriba, Jordi. Hospital Clinic de Barcelona; España. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; EspañaFil: Barbera, Albert. Hospital Clinic de Barcelona; EspañaFil: del Zotto, Hector Herminio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; ArgentinaFil: Nadal, Belen. Hospital Clinic de Barcelona; España. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; EspañaFil: Piquer, Sandra. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España. Hospital Clinic de Barcelona; EspañaFil: Sánchez Pla, Alex. Universidad Autónoma de Barcelona. Hospital Vall D' Hebron; España. Universidad de Barcelona; EspañaFil: Gagliardino, Juan Jose. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); ArgentinaFil: Gomis, Ramon. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España. Hospital Clinic de Barcelona; EspañaBioMed Central2009-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/96573Altirriba, Jordi; Barbera, Albert; del Zotto, Hector Herminio; Nadal, Belen; Piquer, Sandra; et al.; Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach; BioMed Central; BMC Genomics; 10; 1; 8-2009; 1-131471-2164CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-10-406info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2164-10-406info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:39:59Zoai:ri.conicet.gov.ar:11336/96573instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:39:59.561CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
title |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
spellingShingle |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach Altirriba, Jordi TUNGSTATO CELULAS B DIABETES MASA DE CELULS B |
title_short |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
title_full |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
title_fullStr |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
title_full_unstemmed |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
title_sort |
Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach |
dc.creator.none.fl_str_mv |
Altirriba, Jordi Barbera, Albert del Zotto, Hector Herminio Nadal, Belen Piquer, Sandra Sánchez Pla, Alex Gagliardino, Juan Jose Gomis, Ramon |
author |
Altirriba, Jordi |
author_facet |
Altirriba, Jordi Barbera, Albert del Zotto, Hector Herminio Nadal, Belen Piquer, Sandra Sánchez Pla, Alex Gagliardino, Juan Jose Gomis, Ramon |
author_role |
author |
author2 |
Barbera, Albert del Zotto, Hector Herminio Nadal, Belen Piquer, Sandra Sánchez Pla, Alex Gagliardino, Juan Jose Gomis, Ramon |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
TUNGSTATO CELULAS B DIABETES MASA DE CELULS B |
topic |
TUNGSTATO CELULAS B DIABETES MASA DE CELULS B |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Background: Sodium tungstate is known to be an effective anti-diabetic agent, able to increase beta cell mass in animal models of diabetes, although the molecular mechanisms of this treatment and the genes that control pancreas plasticity are yet to be identified. Using a transcriptomics approach, the aim of the study is to unravel the molecular mechanisms which participate in the recovery of exocrine and endocrine function of streptozotocin (STZ) diabetic rats treated with tungstate, determining the hyperglycemia contribution and the direct effect of tungstate. Results: Streptozotocin (STZ)-diabetic rats were treated orally with tungstate for five weeks. Treated (STZ)-diabetic rats showed a partial recovery of exocrine and endocrine function, with lower glycemia, increased insulinemia and amylasemia, and increased beta cell mass achieved by reducing beta cell apoptosis and raising beta cell proliferation. The microarray analysis of the pancreases led to the identification of three groups of differentially expressed genes: genes altered due to diabetes, genes restored by the treatment, and genes specifically induced by tungstate in the diabetic animals. The results were corroborated by quantitative PCR. A detailed description of the pathways involved in the pancreatic effects of tungstate is provided in this paper. Hyperglycemia contribution was studied in STZ-diabetic rats treated with phloridzin, and the direct effect of tungstate was determined in INS-1E cells treated with tungstate or serum from untreated or treated STZ-rats, observing that tungstate action in the pancreas takes places via hyperglycemia-independent pathways and via a combination of tungstate direct and indirect (through the serum profile modification) effects. Finally, the MAPK pathway was evaluated, observing that it has a key role in the tungstate-induced increase of beta cell proliferation as tungstate activates the mitogen-activated protein kinase (MAPK) pathway directly by increasing p42/p44 phosphorylation and indirectly by decreasing the expression of raf kinase inhibitor protein (Rkip), a negative modulator of the pathway. Conclusion: In conclusion, tungstate improves pancreatic function through a combination of hyperglycemia-independent pathways and through its own direct and indirect effects, whereas the MAPK pathway has a key role in the tungstate-induced increase of beta cell proliferation. Fil: Altirriba, Jordi. Hospital Clinic de Barcelona; España. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España Fil: Barbera, Albert. Hospital Clinic de Barcelona; España Fil: del Zotto, Hector Herminio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina Fil: Nadal, Belen. Hospital Clinic de Barcelona; España. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España Fil: Piquer, Sandra. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España. Hospital Clinic de Barcelona; España Fil: Sánchez Pla, Alex. Universidad Autónoma de Barcelona. Hospital Vall D' Hebron; España. Universidad de Barcelona; España Fil: Gagliardino, Juan Jose. Universidad Nacional de La Plata. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina Fil: Gomis, Ramon. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas; España. Hospital Clinic de Barcelona; España |
description |
Background: Sodium tungstate is known to be an effective anti-diabetic agent, able to increase beta cell mass in animal models of diabetes, although the molecular mechanisms of this treatment and the genes that control pancreas plasticity are yet to be identified. Using a transcriptomics approach, the aim of the study is to unravel the molecular mechanisms which participate in the recovery of exocrine and endocrine function of streptozotocin (STZ) diabetic rats treated with tungstate, determining the hyperglycemia contribution and the direct effect of tungstate. Results: Streptozotocin (STZ)-diabetic rats were treated orally with tungstate for five weeks. Treated (STZ)-diabetic rats showed a partial recovery of exocrine and endocrine function, with lower glycemia, increased insulinemia and amylasemia, and increased beta cell mass achieved by reducing beta cell apoptosis and raising beta cell proliferation. The microarray analysis of the pancreases led to the identification of three groups of differentially expressed genes: genes altered due to diabetes, genes restored by the treatment, and genes specifically induced by tungstate in the diabetic animals. The results were corroborated by quantitative PCR. A detailed description of the pathways involved in the pancreatic effects of tungstate is provided in this paper. Hyperglycemia contribution was studied in STZ-diabetic rats treated with phloridzin, and the direct effect of tungstate was determined in INS-1E cells treated with tungstate or serum from untreated or treated STZ-rats, observing that tungstate action in the pancreas takes places via hyperglycemia-independent pathways and via a combination of tungstate direct and indirect (through the serum profile modification) effects. Finally, the MAPK pathway was evaluated, observing that it has a key role in the tungstate-induced increase of beta cell proliferation as tungstate activates the mitogen-activated protein kinase (MAPK) pathway directly by increasing p42/p44 phosphorylation and indirectly by decreasing the expression of raf kinase inhibitor protein (Rkip), a negative modulator of the pathway. Conclusion: In conclusion, tungstate improves pancreatic function through a combination of hyperglycemia-independent pathways and through its own direct and indirect effects, whereas the MAPK pathway has a key role in the tungstate-induced increase of beta cell proliferation. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-08 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/96573 Altirriba, Jordi; Barbera, Albert; del Zotto, Hector Herminio; Nadal, Belen; Piquer, Sandra; et al.; Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach; BioMed Central; BMC Genomics; 10; 1; 8-2009; 1-13 1471-2164 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/96573 |
identifier_str_mv |
Altirriba, Jordi; Barbera, Albert; del Zotto, Hector Herminio; Nadal, Belen; Piquer, Sandra; et al.; Molecular mechanisms of tungstate-induced pancreatic plasticity: A transcriptomics approach; BioMed Central; BMC Genomics; 10; 1; 8-2009; 1-13 1471-2164 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-10-406 info:eu-repo/semantics/altIdentifier/doi/10.1186/1471-2164-10-406 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
BioMed Central |
publisher.none.fl_str_mv |
BioMed Central |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614426551910400 |
score |
13.070432 |